دورية أكاديمية
Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031
| العنوان: | Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031 |
|---|---|
| المؤلفون: | Cash, Thomas, Krailo, Mark D, Buxton, Allen B, Pawel, Bruce R, Healey, John H, Binitie, Odion, Marcus, Karen J, Grier, Holcombe E, Grohar, Patrick J, Reed, Damon R, Weiss, Aaron R, Gorlick, Richard, Janeway, Katherine A |
| المصدر: | Maine Medical Center |
| بيانات النشر: | MaineHealth Knowledge Connection |
| سنة النشر: | 2023 |
| المجموعة: | MaineHealth Knowledge Connection |
| مصطلحات موضوعية: | Oncology, Pediatrics |
| الوصف: | JCO Long-term outcomes from Children's Oncology Group study AEWS0031 were assessed to determine whether the survival advantage of interval-compressed chemotherapy (ICC) was maintained over 10 years in patients with localized Ewing sarcoma (ES). AEWS0031 enrolled 568 eligible patients. Patients were randomly assigned to receive vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide alternating once every 3 weeks (standard timing chemotherapy [STC]) versus once every 2 weeks (ICC). For this updated report, one patient was excluded because of uncertainty of original diagnosis. The 10-year event-free survival (EFS) was 70% with ICC compared with 61% with STC ( = .03), and 10-year overall survival (OS) was 76% with ICC compared with 69% with STC ( = .04). There was no difference in the 10-year cumulative incidence of second malignant neoplasms (SMNs; [see Data Supplement, online only] = .5). A test for interaction demonstrated that ICC provided greater risk reduction for patients with tumor volume ≥200 mL than for patients with tumorsmL, but no evidence for a significant interaction in other subgroups defined by age, primary site, and histologic response. With longer-term follow-up, ICC for localized ES is associated with superior EFS and OS without an increased risk for SMN compared with STC. ICC is associated with improved outcomes even in adverse-risk patient groups. |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| العلاقة: | https://knowledgeconnection.mainehealth.org/mmc/3360Test; https://pubmed.ncbi.nlm.nih.gov/37651654Test/ |
| الإتاحة: | https://knowledgeconnection.mainehealth.org/mmc/3360Test https://pubmed.ncbi.nlm.nih.gov/37651654Test/ |
| رقم الانضمام: | edsbas.C5FB23CB |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |